

CITATION REPORT

List of articles citing

Hydroxychloroquine-induced myopathy

DOI: 10.1097/rhu.ob013e3181c47ec8

Journal of Clinical Rheumatology, 2010, 16, 28-31.

Source: <https://exaly.com/paper-pdf/47573205/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
32	Current awareness: Pharmacoepidemiology and drug safety. <i>Pharmacoepidemiology and Drug Safety</i> , 2010 , 19, i-xiii	2.6	
31	Chloroquine-induced myopathy. <i>Lupus</i> , 2011 , 20, 773-4	2.6	8
30	Discovering thiamine transporters as targets of chloroquine using a novel functional genomics strategy. <i>PLoS Genetics</i> , 2012 , 8, e1003083	6	18
29	Fatal antimalarial-induced cardiomyopathy: report of 2 cases. <i>Journal of Clinical Rheumatology</i> , 2012 , 18, 363-6	1.1	23
28	Hydroxychloroquine: from malaria to autoimmunity. <i>Clinical Reviews in Allergy and Immunology</i> , 2012 , 42, 145-53	12.3	348
27	Electrodiagnosis of myotonic disorders. <i>Physical Medicine and Rehabilitation Clinics of North America</i> , 2013 , 24, 209-20	2.3	15
26	Myopathy complicating lupus pregnancy. <i>Journal of Clinical Rheumatology</i> , 2013 , 19, 132-3	1.1	1
25	Outcome of early clinical trials of the combination of hydroxychloroquine with chemotherapy in cancer. <i>Autophagy</i> , 2014 , 10, 1478-80	10.2	69
24	Myopathies of Systemic Disease. 2015 , 679-696		
23	Safety of treatments for primary Sjögren's syndrome. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 513-24	4.1	9
22	Hydroxychloroquine in systemic lupus erythematosus (SLE). <i>Expert Opinion on Drug Safety</i> , 2017 , 16, 411-419	4.1	153
21	Therapeutic monitoring of the immuno-modulating drugs in systemic lupus erythematosus. <i>Expert Review of Clinical Immunology</i> , 2017 , 13, 35-41	5.1	21
20	Curvilinear bodies are associated with adverse effects on muscle function but not with hydroxychloroquine dosing. <i>Clinical Rheumatology</i> , 2017 , 36, 689-693	3.9	5
19	Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature. <i>Drug Safety</i> , 2018 , 41, 919-931	5.1	195
18	Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review. <i>Clinical Drug Investigation</i> , 2018 , 38, 653-671	3.2	152
17	Muscle Toxicity of Drugs: When Drugs Turn Physiology into Pathophysiology. <i>Physiological Reviews</i> , 2020 , 100, 633-672	47.9	14
16	Side Effects of Chloroquine and Hydroxychloroquine on Skeletal Muscle: a Narrative Review. <i>Current Pharmacology Reports</i> , 2020 , 6, 1-9	5.5	10

15	Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review. <i>Travel Medicine and Infectious Disease</i> , 2020 , 35, 101735	8.4	71
14	Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: Risks and benefits at the time of COVID-19 pandemic. <i>Journal of Diabetes</i> , 2020 , 12, 659-667	3.8	19
13	[A rare cause of impaired general condition: Muscular and cardiac toxicity of antimalarials]. <i>Revue De Medecine Interne</i> , 2020 , 41, 335-338	0.1	3
12	Hydroxychloroquine in the COVID-19 pandemic era: in pursuit of a rational use for prophylaxis of SARS-CoV-2 infection. <i>Expert Review of Anti-Infective Therapy</i> , 2021 , 19, 5-16	5.5	15
11	COVID-19. 2021 , 203-210		
10	Hydroxychloroquine Effects on TLR Signalling: Underexposed but Unneglectable in COVID-19. <i>Journal of Immunology Research</i> , 2021 , 2021, 6659410	4.5	2
9	The toxic effects of chloroquine and hydroxychloroquine on skeletal muscle: a systematic review and meta-analysis. <i>Scientific Reports</i> , 2021 , 11, 6589	4.9	1
8	Repurposed drug against COVID-19: nanomedicine as an approach for finding new hope in old medicines. <i>Nano Express</i> , 2021 , 2, 022007	2	2
7	Treatment and Management of Infectious, Granulomatous, and Toxic Neuromuscular Disorders. 2022 , 345-379		
6	The journey of antimalarial drugs against SARS-CoV-2: Review article. <i>Informatics in Medicine Unlocked</i> , 2021 , 24, 100604	5.3	17
5	Hydroxychloroquine in COVID-19 Patients: Pros and Cons. <i>Frontiers in Pharmacology</i> , 2020 , 11, 597985	5.6	13
4	Hydroxychloroquine-induced hyperpigmentation in a 14-year-old female with systemic lupus erythematosus. <i>Drugs in Context</i> , 2020 , 9,	5.2	1
3	Hydroxychloroquine and Fabry Disease: Three Case Reports Examining an Unexpected Pathologic Link and a Review of the Literature. <i>Case Reports in Rheumatology</i> , 2022 , 2022, 1-6	0.8	
2	How toxic is an old friend? A review of the safety of hydroxychloroquine in clinical practice.		0
1	Chloroquine chaos and COVID-19: Smart delivery perspectives through pH sensitive polymers/micelles and ZnO nanoparticles. 2023 , 16, 104468		0